In Vivo Toxicology

MuriGenics specializes in rodent preclinical non-GLP toxicology studies, directed toward preliminary screening and safety profiling of test articles.

As with all of our In Vivo services, we guarantee continued communication during on-going studies and will contact you directly with any questions or concerns. This guarantees that any data collected is both biologically and clinically reliable and relevant. Further, any valued data that appears to warrant a change in protocol can be discussed, giving the client the flexibility to modify their existing protocols.


Rats and Mice

Means of Administration
  • Oral
  • Subcutaneous
  • Intraperitoneal
  • Intramuscular
  • Intravenous
  • Topical
  • Slow-Infusion
Types of Studies Performed
  • Maximum Tolerated Dose (MTD)
  • Singe-Dose (Acute)
  • Chronic Toxicity
  • Irritation and Sensitization
Screening for Compound-Related Cardiotoxic Effects

An important part of the preclinical safety profiling of a pharmacological agent involves screening for cardiotoxic effects. Many toxic drug effects are manifested in changes to the rhythm of the heart, these include: slowing (bradycardia) or quickening (tachycardia) of the heart rate, heart rate variability and/or alterations in the length of the intervals within the sinus rhythm. These changes are reflected in electrocardiogram (ECG) traces. Used in conjunction with clinical observations, an ECG can detect potentially fatal drug-induced cardiac arrhythmias. One example is torsades de pointes, a potentially fatal polymorphic ventricular tachycardia that can be triggered or exacerbated by pharmacological agents.

Cardiotoxicity can be a direct or an indirect effect of a novel compound, or it can be the result of drug-drug and/or drug-genotype interaction. A common example of a drug-genotype (pharmacogenetic) interaction is the occurrence of torsades de pointes in individuals with inherited Long-QT syndrome following the administration of certain pharmacological agents that extend the QT interval. Detecting drug-genotype interactions on cardiac functioning is important because cardiotoxic drug effects, including those that involve the elongation of the QT interval, are some of the most common reasons for the withdrawal of a drug from the market, yet may exist only in a susceptible percentage of the population small enough to be overlooked in a study the size of a standard clinical trial. Screening novel drugs preclinically in animals with known genetic susceptibility to specific cardiac conditions may help detect cardiotoxic effects of novel drugs in the early phases of drug development before they enter expensive clinical trials. Scientists at MuriGenics can help you choose a strain that is appropriate for the screening of drug-genotype interactive cardiotoxicity.

ECGenie: Non-invasive Electrocardiogram (ECG) for Small Animals

MuriGenics offers non-invasive electrocardiogram (ECG) screening through the use of the ECGenie instrument. The ECGenie measures ECGs from the paws of conscious small animals using a footplate equipped with electrodes positioned for maximum contact. Data can be acquired efficiently in conscious un-restrained rodents with this platform. Read more regarding the ECGenie and also view sample data.

Toxicity Blood Panel

We also offer a blood panel for measuring serum parameters of drug toxicity. These include:

  • Albumin
  • Alkaline Phosphatase
  • Alanine Aminotransferase
  • Amylase
  • Aspartate Aminotransferase
  • Blood Urea Nitrogen
  • Calcium
  • Cholesterol
  • Creatinine
  • Glucose
  • Phosphate
  • Total Protein
  • Globulin (calculated)